NEW YORK (GenomeWeb News) – Biodesix today announced the closing of a $12 million extension of its Series D financing round.
The funds will support commercialization of its VeriStrat blood-based test for non-small cell lung cancer, as well as clinical validation studies, product development, and ongoing collaborations with biotechnology and pharmaceutical companies.
The Boulder-based molecular diagnostic firm closed on the Series D round in July 2011, raising $20 million. Biodesix said it plans to pursue clearance from the US Food and Drug Administration for VeriStrat, a mass spectrometry-based test performed out of the company's CLIA laboratory to help guide physicians treating patients with NSCLC.